The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.
 
Nataliya Mar
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Eisai; Merck
Research Funding - Gilead Sciences
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Allergan (I); AstraZeneca; Bausch and Lomb (I); Bristol-Myers Squibb; CG Oncology; enGene; Ferring; ImmunityBio; Johnson & Johnson; pacific edge; Pfizer; Photocure; Protara Therapeutics; Sesen Bio; Storz; Urogen pharma
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Pfizer; CG Oncology; enGene; Ferring; ImmunityBio; Johnson & Johnson/Janssen; pacific edge; Pfizer; Photocure; Taris; Urogen pharma; UroToday
Research Funding - Photocure
Travel, Accommodations, Expenses - Janssen Oncology; Photocure
 
David Benjamin
Consulting or Advisory Role - AiMed; Astellas Pharma; AVEO; Bayer; Eisai; EMD Serono; Exelixis; Janssen; Seagen
Speakers' Bureau - Merck
Travel, Accommodations, Expenses - DAVA Oncology; Merck; Seagen
 
Anishka D'souza
No Relationships to Disclose
 
Michael Daneshvar
Consulting or Advisory Role - CG Oncology; ImmunityBio; Pfizer
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AimedBio; AstraZeneca; aveo; Bayer; Bicycle Therapeutics; Eisai; Exelixis; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Amgen; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Myovant Sciences; Pfizer; Sanofi
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eikon Therapeutics; Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); navir (Inst); Novartis (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Janssen